The Unexpected Positive Side Effects of GLP-1s

This episode of All of It explores the unexpected positive side effects of GLP-1 medications like Ozempic, Wegovy, and Mounjaro, which were originally developed for diabetes and weight loss but are now being used off-label for a wide range of conditions. Host Alison Stewart interviews Julia Ballouz, a contributing opinion writer for The New York Times, who discusses her investigative piece, 'The Great Ozempic Experiment.' Patients are reporting remarkable benefits beyond weight loss, including relief from chronic migraines, irritable bowel syndrome, post-concussion syndrome, reduced cravings for alcohol and food, improved cognition, and decreased inflammation—some even describing a 'fog lifting' effect. Ballouz shares survey data showing over 60% of users would continue taking the drugs even if they weren’t effective for weight loss, highlighting a shift in perception from a purely cosmetic treatment to a potential multi-system wellness tool. However, the episode also acknowledges serious risks, such as dehydration, gastrointestinal distress, and long-term unknowns, especially in children. The conversation underscores a critical tension: while these drugs offer real hope for people with diet-related diseases, they are being used in a vast, unregulated experiment—particularly in youth—raising urgent questions about prevention, access, and long-term safety.